

## CORPORATE FACT SHEET

### Overview

**Vigilant Biosciences** is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer.

### Technology

We utilize **proprietary biomarker** technology (**THE SCIENCE OF EARLIER**®) using innovative solutions for the early detection and intervention of cancer. Our initial focus is **oral cancer** diagnostics.

### Products

The Vigilant Biosciences OncAlert® Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are **simple, accurate and cost-effective** and empower healthcare practitioners to improve potential outcomes through earlier intervention.

The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark™ Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies.

### Leadership

Matthew H.J. Kim, J.D.	<i>Founder, Chief Executive Officer</i>
Elizabeth Franzmann, M.D.	<i>Scientific Founder, Chief Scientific Officer</i>
Michael Donovan, Ph.D., M.D.	<i>Chief Clinical Officer</i>
Sally Bowden	<i>VP, Regulatory, Quality &amp; Operations &amp; GM of OncAlert Labs, LLC</i>
Robert T. Hamilton, C.P.A.	<i>Chief Financial Officer</i>
Currently Recruiting	<i>Chief Business Officer</i>

### Board of Directors

Matthew H.J. Kim, J.D., Timothy Barabe, Eric Stone, Stuart Heap, Linda Niessen, D.M.D.

### Founded:

2011 and headquartered in Fort Lauderdale, FL

### Investors:

Vigilant Biosciences is proud to be working with the teams at venVelo, White Owl Ventures, The Florida Institute for the Commercialization of Public Research and University of Miami, as well as a group of private and angel investors with a commitment to the life sciences.

### CONTACT INFORMATION

Vigilant Biosciences, Inc.  
6301 NW 5th Way, Suite 1500  
Ft. Lauderdale FL 33309  
954-487-1740

### MEDIA CONTACT

Jennifer Moritz  
Zero to Five  
917-748-4006  
[jmoritz@0to5.com](mailto:jmoritz@0to5.com)

### INVESTOR CONTACT

Paula Schwartz  
Rx Communications Group  
917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)